Loading
A phase 1 trial of Mavorixafor and Pembrolizumab in Melanoma, run by X4 Pharmaceuticals, completed.
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma is a phase 1 interventional study registered as NCT02823405 by X4 Pharmaceuticals, with 16 participants recorded, started 2016-09-15 and reaching its primary completion in 2018-03-15. Interventions recorded: X4P-001, Pembrolizumab. Conditions recorded: Melanoma.
Linked to the drug Mavorixafor because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Shares X4 Pharmaceuticals, Mavorixafor and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.